Fund Evaluator:
ProFunds Biotechnology UltraSector Inv (BIPIX)
Follow This Fund
Best Performing in Trading--Leveraged Equity Over the Last Year
| 193.4% | ProFunds UltraJapan Inv (UJPIX) |
| 149.6% | ProFunds Biotechnology UltraSector Inv (BIPIX) |
| 130.1% | ProFunds Semiconductor UltraSector Inv (SMPIX) |
| 123.5% | Oil Equipment&Svcs UltraSector Pro Inv (OEPIX) |
| 99.4% | ProFunds Pharmaceuticals UltraSector Inv (PHPIX) |
Fund Details
ProFunds Biotechnology UltraSector Inv Overview
ProFunds Biotechnology UltraSector Inv (BIPIX) is a passively managed Miscellaneous Trading--Leveraged Equity fund. ProFunds launched the fund in 2000.
The investment seeks daily investment results, before fees and expenses, that correspond to one and one-half times (1.5x) the daily performance of the S&P Biotechnology Select Industry Index. The index is designed to measure the performance of biotechnology companies included in the S&P Total Market Index. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.
About ProFunds Biotechnology UltraSector Inv (BIPIX)
There are 2 members of the management team with an average tenure of 10.46 years: Michael Neches (2013), Tarak Davé (2018). Management tenure is more important for actively managed funds than passive index funds.
The fund has 2 primary benchmarks: S&P 500 (TR) (1970) index with a weighting of 100% and S&P Biotechnology Select Industry TR USD index with a weighting of 150%. ProFunds Biotechnology UltraSector Inv has 161 securities in its portfolio. The top 10 holdings constitute 108.4% of the fund’s assets. The fund meets the SEC requirement of being classified as a nondiversified fund. The fund is not considered to have an ESG focus with its investment selection and management.
ProFunds Biotechnology UltraSector Inv is part of the Other global asset class and is within the Miscellaneous fund group. ProFunds Biotechnology UltraSector Inv has 2.1% of its portfolio invested in foreign issues. The overall assets allocated to domestic stock is 123.1%. There is 2.1% allocated to foreign stock, and 0.0% is allocated to preferred stocks. The bond allocation as a percentage of total assets is 0.0% (0.0% domestic bond, 0.0% foreign bond and 0.0% convertible bond). ProFunds Biotechnology UltraSector Inv has -23.0% of the portfolio in cash.
Assets Under Management
The fund has $131 million in total assets, which is above the $77 million average for the Trading--Leveraged Equity category. Normally, lower assets under management translates to higher average expense ratios, and greater total assets are desired. However, for some investment categories, such as small-cap investing, it may be difficult for the manager to fully employ the desired active strategy if assets grow too large or too quickly.
BIPIX Performance and Fees
The expense ratio measures how much of a fund’s assets are used for administrative expenses and operating expenses, including adviser fees and fees for the transfer agent and custodial services. The ProFunds Biotechnology UltraSector Inv expense ratio is high compared to funds in the Trading--Leveraged Equity category. ProFunds Biotechnology UltraSector Inv has an expense ratio of 1.52%, which is 25% lower than its category average, making the fund expense ratio grade a A. While it is difficult to predict returns, it is known that high annual expense ratios reduce your rate of return, and excessive fees are difficult to overcome. Active management normally comes with higher expense ratios than passive index management. Certain investment categories such as small company and foreign also normally have higher expense ratios. It is best to compare fund expense ratios against the category averages for meaningful assessments.
High portfolio turnover can translate to higher expenses and lower aftertax returns. ProFunds Biotechnology UltraSector Inv has a portfolio turnover rate of 52%, indicating that holds its assets around 0.0 years. By way of comparison, the average portfolio turnover is 401% for the Trading--Leveraged Equity category.
Recently, in the month of June 2026, ProFunds Biotechnology UltraSector Inv returned 23.7%, which earned it a grade of A, as the Trading--Leveraged Equity category had an average return of 1.0%. The letter grades of A, B, C, D and F are based upon relative rankings within the investment category. A grade of A, for example, would indicate that the return is in the highest 20% for that time period compared to all funds in that category.
ProFunds Biotechnology UltraSector Inv has a trailing yield of 0.24%, which is below the 1.04% category average. The fund normally distributes its income annually and its capital gains annually.
It’s natural to seek the best-performing investments, but you must consider the relationship between risk and return and the impact of costs and taxes on your realized returns.
ProFunds Biotechnology UltraSector Inv Grades
Year to date, the fund has returned 43.1%, 21.1 percentage points better than the category, which translates into a grade of A. The fund has returned 149.6% over the past year (grade of A), 29.2% over the past three years (grade of B) and 14.4% per year over the past five years (grade of B) and 15.6% per year over the past 10 years (grade of B).
For more mutual fund grades, analysis and screening tools to help your investment discovery, join AAII for a $2, full-access trial. Learn more here: https://invest.aaii.com/membership.
Otherwise, for more information about ProFunds Biotechnology UltraSector Inv, including its riskiness, submit your email to unlock the rest of the article.
Gain access to exclusive AAII member-only content.
BIPIX Trailing NAV Total Returns Data as of 6/30/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| BIPIX Return (NAV) | 23.7% | 35.9% | 149.6% | 29.2% | 14.4% | 15.6% |
| BIPIX Grade | A | B | A | B | B | B |
| +/- Category | 22.7% | 11.6% | 101.2% | 3.4% | 4.1% | 0.3% |
| Trading--Leveraged Equity Avg | 1.0% | 24.4% | 48.4% | 25.7% | 10.2% | 15.3% |
| BIPIX Tax Cost Ratio | na | na | 0.1% | 3.7% | 3.3% | 2.5% |
BIPIX Annual NAV Total ReturnsData as of 6/30/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| BIPIX Return (NAV) | 43.1% | 48.0% | -5.2% | 10.1% | -13.4% | 23.8% | 20.1% | 23.6% | -12.2% | 34.7% | -23.8% |
| BIPIX Grade | A | A | F | D | A | C | C | F | B | C | F |
| +/- Category | 21.1% | 16.8% | -23.8% | -25.9% | 15.5% | -3.1% | -3.3% | -20.3% | 5.4% | -3.0% | -43.1% |
| Trading--Leveraged Equity Avg | 22.0% | 31.2% | 18.6% | 36.0% | -28.9% | 26.9% | 23.4% | 44.0% | -17.6% | 37.7% | 19.3% |
| Risk Measures | |
| Standard Deviation: | 38.5% |
| Total Risk Index: | 3.17 - High |
| Category Risk Index: | 1.25 - High |
| Category Risk Grade: | F (82% Rank) |
| Beta: | 1.60 |
| R-Squared: | 29% |
| Leveraged Fund: | Yes |
| Inverse Fund: | No |
| Portfolio Characteristics | |
| Equity Investment Style: | Small-Cap Blend |
| Bond Investment Style: | na |
| Yield: | 0.2% |
| Dividend Distribution: | Annually |
| Cap Gains Distribution: | Annually |
| Total Assets: | $135 Mil |
| Fund Total Assets: | $ 131 Mil |
| Share Class Type: | Inv |
| Portfolio Turnover: | 52% |
Management Team
| Number of Managers: 2 | |||
| Longest Tenure: 12.8 years | |||
| Average Tenure: 10.5 years | |||
| Managers (Year): Neches Michael (2013), Davé Tarak (2018) | |||
Portfolio Composition (as of 4/30/26)
| # of Holdings: | 161 |
| % in Top 10 Holdings: | 108.4% |
| Fund is Non-Diversified: | Yes |
| % in Foreign Issues: | 2.1% |
Portfolio Allocation |
|
| Domestic Stock: | 123.1% |
| Foreign Stock: | 2.1% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | -2.2% |
| Cash: | -23.0% |
Purchase Information
| Fund Family: | ProFunds |
| Phone Number: | 888-776-3637 |
| Website: | www.profunds.com |
| Status: | Open |
| Inception Date: | June 19, 2000 |
| Min. Initial Purchase: | $15,000 |
| Min. Initial IRA Purchase: | $ 0 |
| True No-Load: | Yes |
| Front Load Maximum: | 0.00% |
| Deferred Charge Maximum: | 0.00% |
| Redemption Charge Maximum: | 0.00% |
| 12b-1 Fee: | 0.00% |
Expenses and Fees | |
| Expense Ratio (%): | 1.52% ( Rating : High ) |
| Category Average Expense Ratio (%): | 2.03% |
| Share Class: | ProFunds Biotechnology UltraSector Inv |
| Min. Subsequent Purchase: | $ 0 |
| Min. Subsequent IRA Purchase: | $ 0 |
